Radioligand Therapy Market By Radioisotope Type (Beta Emitters, Alpha Emitters, Auger Electron Emitters), By Ligand Type (Peptide-Based Ligands, Monoclonal Antibody-Based Ligands, Small Molecule Ligands), By Application (Prostate Cancer, Neuroendocrine Tumors (NETs), Lung Cancer, Breast Cancer, Lymphoma, Glioblastoma, Others), By Route of Administration (Intravenous Injection, Intratumoral Injection), and By End-User (Hospitals, Specialty Clinics, Cancer Treatment Centers, Research Institutes), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Report Coverage:

By Radioisotope Type

• Beta Emitters
• Alpha Emitters
• Auger Electron Emitters

By Ligand Type

• Peptide-Based Ligands
• Monoclonal Antibody-Based Ligands
• Small Molecule Ligands

By Application

• Prostate Cancer
• Neuroendocrine Tumors (NETs)
• Lung Cancer
• Breast Cancer
• Lymphoma
• Glioblastoma
• Others

By Route of Administration

• Intravenous Injection
• Intratumoral Injection

By End-User

• Hospitals
• Specialty Clinics
• Cancer Treatment Centers
• Research Institutes

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• Novartis
• Bayer AG
• Ipsen
• Eli Lilly and Company
• Point Biopharma
• Actinium Pharmaceuticals
• Progenics Pharmaceuticals
• Theragnostics
• Radiomedix
• MolMed S.p.A.
• Orano Med
• Clarity Pharmaceuticals
• Alpha Tau Medical
• Nordic Nanovector
• Aspreva Pharmaceuticals